UK trial aims to repurpose existing drugs for rare and Hard-to-Treat cancers
Disease control
Not yet recruiting
This trial is testing if two already-approved cancer drugs, dabrafenib and trametinib, can help patients with rare cancers or common cancers that have a rare, specific genetic change called a BRAF V600 mutation. The drugs are already used for some cancers like melanoma, but resea…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC